InventisBio (SH:688382) Zheng Quan Zhi Xing·2025-05-30 11:54Core Viewpoint - The company is committed to enhancing operational efficiency and management quality through its "Quality Improvement and Efficiency Enhancement" action plan for 2025, aiming to strengthen its core competitiveness and market image while protecting the rights of investors, especially small and medium-sized investors [1] Group 1: Business Strategy and Development - The company focuses on innovative drug research and development in major disease areas such as oncology, metabolism, and autoimmune diseases, aiming to address unmet clinical needs with globally competitive products [1][3] - The company has two authorized products on the market, one in the registration clinical trial phase, two in Phase II clinical trials, and multiple preclinical projects, indicating a strong R&D pipeline [2] - The company plans to expand the clinical exploration of its D-2570 product in multiple autoimmune disease treatment areas, with a Phase II clinical trial for ulcerative colitis approved in March 2025 [2] Group 2: R&D Capabilities - The company has established a comprehensive R&D system that enhances the success rate of its products and shortens the drug development cycle through precise target screening and clinical development [2][4] - The company has a strong R&D team with over 90% of its workforce dedicated to research, and the team leaders possess extensive experience in multinational pharmaceutical companies [5][6] - The company has applied for 370 domestic and international invention patents, with 129 granted, emphasizing its commitment to innovation and intellectual property protection [5] Group 3: Governance and Investor Relations - The company is enhancing its governance structure by clarifying the responsibilities of the board and independent directors to protect the rights of minority investors [7] - The company prioritizes high-quality information disclosure and investor communication, utilizing various channels to keep investors informed about its operations and financial status [8][9] - The company plans to implement a new round of equity incentive plans to align the interests of shareholders and the core team, fostering long-term development [6] Group 4: Funding and Investment Efficiency - The company is optimizing its fundraising projects to enhance the efficiency of its R&D investments, including the integration and upgrade of its existing R&D and operational facilities [6] - The investment in key projects will support the clinical trial processes and the exploration of new indications, thereby strengthening the company's competitive edge in innovative drug development [6]